Topics:

Progression-Free Survival After Six Years (Median) Follow-Up of the First Clinical Trial of Rituximab/CHOP Chemoimmunotherapy

Progression-Free Survival After Six Years (Median) Follow-Up of the First Clinical Trial of Rituximab/CHOP Chemoimmunotherapy

The first clinical trial of rituximab (Rituxan) in combination with CHOP chemotherapy (cyclophosphamide [Cytoxan, Neosar], doxorubicin HCl, vincristine [Oncovin], prednisone) was initiated in April 1994 (J Clin Oncol 17:268, 1999). This study showed the safety and efficacy of the combination in low-grade non-Hodgkin’s lymphoma (NHL) and enabled progression to phase II trials in intermediate-grade NHL (J Clin Oncol 19:389, 2001). In addition, the Groupe d’Etude des Lymphomes de l’Adulte (GELA) randomized phase III study has shown a statistically significant increase in progression-free survival for rituximab/CHOP as compared with CHOP alone (Blood 96:223a [abstract 950]).

Characteristics of the 40 patients with low-grade/follicular NHL (International Working Formulation A, 9 patients; IWF B, 17; IWF C, 13; IWF D, 1) entered on our study are as follows: 21 males, 19 females (31 naive, 9 previously treated); median age, 48 years (range: 29-77 years); and 83% stage III/IV at diagnosis. CHOP was administered at standard doses every 3 weeks for six cycles, along with six infusions of rituximab (375 mg/m²/dose). Two doses of rituximab were given both at the beginning and end of therapy, as well as single doses before the third and fifth cycles of CHOP.

Adverse events were mostly grade 1/2. Of all events, 17% were grade 3/4 and consisted primarily of hematologic or infectious toxicities felt to be associated with CHOP chemotherapy. Human antimouse antibody and human antichimeric antibody responses were not seen. Of 40 patients registered, 38 were treated (two received no therapy) and 35 completed all therapy.

All patients treated responded (58% complete responses [CR], 42% partial responses [PR]), and the overall response rate in patients who completed all therapy was 100% (63% CR, 37% PR). Median duration of response is 63.6+ months, with median progression-free survival (PFS) not reached after a median observation time of 65.1+ months. Twenty-one patients are still in remission at 46.8+ and up to 86.3+ months. Seven of eight bcl-2-positive patients converted to polymerase chain reaction (PCR) negativity in blood and marrow (molecular complete remissions). Of these seven patients, six remain in CR and four remain PCR negative by serial analyses.

Naive and previously treated patients had similar demographics. Kaplan-Meier graphs for PFS are not significantly different, although there is a trend for longer time to progression for the naive patients (P = .409, log rank). The PR and CR patients had similar demographics. Kaplan-Meier graphs for PFS show a significantly longer time to progression for the CR patients (P = .017, log rank).

CONCLUSION: Rituximab can be safely combined with CHOP, resulting in a high response rate and a prolonged PFS, without causing significant additional toxicity. The conversion of bcl-2 from positive to negative by PCR in blood and marrow indicates clearance of minimal residual disease. The prolonged PFS seen in this study exceeds that reported in CHOP (alone) studies.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

 
Loading comments...
Please Wait 20 seconds or click here to close